Tempo reale stimato
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
16,07 USD | +5,65% | +5,10% | +135,63% |
Attività
Numero di dipendenti: 100
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Novel Antibody-based Therapeutic Products
100,0
%
| 49 | 100,0 % | 84 | 100,0 % | +71,15% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
80,4
%
| 46 | 93,9 % | 68 | 80,4 % | +46,60% |
Other Countries
19,6
%
| 3 | 6,1 % | 17 | 19,6 % | +448,70% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Thomas Gad
FOU | Founder | 54 | 01/04/15 |
Michael Rossi
CEO | Chief Executive Officer | 53 | 06/11 |
Bo Kruse
DFI | Director of Finance/CFO | 52 | 01/06/16 |
Vignesh Rajah
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/06/20 |
Joris Wilms
COO | Chief Operating Officer | 50 | 01/11/17 |
Chief Tech/Sci/R&D Officer | 73 | 01/01/16 | |
Sue Smith
PRN | Corporate Officer/Principal | 54 | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
David Gill
BRD | Director/Board Member | 69 | 01/12/17 |
Director/Board Member | 54 | 01/09/15 | |
James Healy
CHM | Chairman | 58 | 01/11/17 |
Ashutosh Tyagi
BRD | Director/Board Member | 47 | 01/11/17 |
Bo Kruse
DFI | Director of Finance/CFO | 52 | 01/06/16 |
Gérard Ber
BRD | Director/Board Member | 66 | 11/12/18 |
Michael Rossi
CEO | Chief Executive Officer | 53 | 06/11 |
Thomas Gad
FOU | Founder | 54 | 01/04/15 |
Laura Hamill
BRD | Director/Board Member | 60 | 01/04/20 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 43 777 105 | 37 409 819 ( 85,46 %) | 0 | 85,46 % |
Coordinate società
Settore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+135,63% | 667 Mln | |
-2,33% | 102 Mrd | |
+2,51% | 96,09 Mrd | |
+2,13% | 22,28 Mrd | |
-17,04% | 21,4 Mrd | |
-8,79% | 18,14 Mrd | |
-39,98% | 17,02 Mrd | |
-13,60% | 16,09 Mrd | |
+5,38% | 13,83 Mrd | |
+32,98% | 11,97 Mrd |
- Borsa valori
- Azioni
- Azione YMAB
- Società Y-mAbs Therapeutics, Inc.